Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Horizon Discovery Group plc    HZD   GB00BK8FL363

HORIZON DISCOVERY GROUP PLC

(HZD)
  Report
Delayed Quote. Delayed London Stock Exchange - 02/28 11:35:07 am
137.4 GBp   -6.28%
02/26HORIZON DISCOVERY : Presentation Cowen Annual Health Care Conference
PU
02/04HORIZON DISCOVERY : Confidential submission of Form F-1 to SEC
PU
01/27HORIZON DISCOVERY : Block Listing Six Monthly Return
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Horizon Discovery : Grants a Multi-Product Use License of its GS knockout CHO K1 Cell Line to NGM Bio

share with twitter share with LinkedIn share with facebook
share via e-mail
01/21/2020 | 10:47am EST

Cell line to be used to support research and development of biotherapeutics across therapeutic areas

Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it will license its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line to NGM Biopharmaceuticals, Inc. (“NGM”) (Nasdaq: NGM). A clinical stage biopharmaceutical company based in South San Francisco, California, NGM is focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.

“We are pleased to enter into this licensing agreement with NGM for this GS knockout CHO K1 cell line to support its broad research and development efforts,” commented Dirk Gewert, Business Unit Director, Horizon Discovery. “Horizon aims to empower organizations of all sizes, from large pharmaceutical companies to clinical stage biotechs and early stage startups, to drive efficiencies in biotherapeutic manufacturing. To date, our complete CHO expression system has been licensed to over 50 companies globally, with a number of biotherapeutics expressed in these cells having progressed to investigational new drug (IND) filings.”

Horizon’s proprietary GS knockout CHO K1 cell line and protocols facilitate the development of stable cell lines for the expression of antibodies and other recombinant proteins. The Company also licenses a CHO expression system to pharmaceutical, biotechnology, and biosimilar companies, as well as contract manufacturing organizations. To enable companies to move from the DNA sequence of their potential biotherapeutic to clinical manufacturing as simply and rapidly as possible, the complete system includes the GS knockout CHO K1 cell line, a comprehensive package of supporting documentation, and an expression vector supplied under license from DNATwoPointO, Inc.

For further information on Horizon’s CHO cells please visit: https://www.horizondiscovery.com


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on HORIZON DISCOVERY GROUP PL
02/26HORIZON DISCOVERY : Presentation Cowen Annual Health Care Conference
PU
02/04HORIZON DISCOVERY : Confidential submission of Form F-1 to SEC
PU
01/27HORIZON DISCOVERY : Block Listing Six Monthly Return
PU
01/21HORIZON DISCOVERY : Grants a Multi-Product Use License of its GS knockout CHO K1..
BU
01/14HORIZON DISCOVERY : Exercises Option to Exclusively License Base Editing Technol..
AQ
01/14HORIZON DISCOVERY : to Provide Access to Novel Base Editing Technology
BU
01/14HORIZON DISCOVERY : Update on Base Editing Technology License
PU
01/13HORIZON DISCOVERY : Signs Collaboration and License Agreement with Mammoth Biosc..
BU
2019HORIZON DISCOVERY : Presentation at J.P. Morgan Healthcare Conference
PU
2019HORIZON DISCOVERY : Second Price Monitoring Extn
PU
More news
Financials (GBP)
Sales 2019 62,9 M
EBIT 2019 -6,80 M
Net income 2019 -4,55 M
Finance 2019 20,3 M
Yield 2019 -
P/E ratio 2019 -45,4x
P/E ratio 2020 -23,7x
EV / Sales2019 2,97x
EV / Sales2020 2,91x
Capitalization 207 M
Chart HORIZON DISCOVERY GROUP PLC
Duration : Period :
Horizon Discovery Group plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HORIZON DISCOVERY GROUP PL
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 214,60  GBp
Last Close Price 137,40  GBp
Spread / Highest target 104%
Spread / Average Target 56,2%
Spread / Lowest Target 24,5%
EPS Revisions
Managers
NameTitle
Terrence William Pizzie Chief Executive Officer & Executive Director
Ian David Gilham Executive Chairman
Kim Nichols Head-Global Operations
Jayesh Pankhania Chief Financial Officer & Director
Vishal Kumar Gulati Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
HORIZON DISCOVERY GROUP PLC-8.40%284
CSL LIMITED15.14%94 808
BIOGEN INC.4.50%53 974
SAMSUNG BIOLOGICS CO.,LTD.0.21%26 246
GRIFOLS-1.11%20 625
ALEXION PHARMACEUTICALS-12.36%20 389